These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 32050523)
1. Genetic Base of Behavioral Disorders in Mucopolysaccharidoses: Transcriptomic Studies. Pierzynowska K; Gaffke L; Podlacha M; Węgrzyn G Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32050523 [TBL] [Abstract][Full Text] [Related]
2. Expression of genes involved in apoptosis is dysregulated in mucopolysaccharidoses as revealed by pilot transcriptomic analyses. Brokowska J; Pierzynowska K; Gaffke L; Rintz E; Węgrzyn G Cell Biol Int; 2021 Mar; 45(3):549-557. PubMed ID: 32125037 [TBL] [Abstract][Full Text] [Related]
3. Underestimated Aspect of Mucopolysaccharidosis Pathogenesis: Global Changes in Cellular Processes Revealed by Transcriptomic Studies. Gaffke L; Pierzynowska K; Podlacha M; Hoinkis D; Rintz E; Brokowska J; Cyske Z; Wegrzyn G Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32054071 [TBL] [Abstract][Full Text] [Related]
4. Changes in expressions of genes involved in the regulation of cellular processes in mucopolysaccharidoses as assessed by fibroblast culture-based transcriptomic analyses. Gaffke L; Pierzynowska K; Krzelowska K; Piotrowska E; Węgrzyn G Metab Brain Dis; 2020 Dec; 35(8):1353-1360. PubMed ID: 32886284 [TBL] [Abstract][Full Text] [Related]
5. Why are behaviors of children suffering from various neuronopathic types of mucopolysaccharidoses different? Węgrzyn G; Jakóbkiewicz-Banecka J; Narajczyk M; Wiśniewski A; Piotrowska E; Gabig-Cimińska M; Kloska A; Słomińska-Wojewódzka M; Korzon-Burakowska A; Węgrzyn A Med Hypotheses; 2010 Dec; 75(6):605-9. PubMed ID: 20732748 [TBL] [Abstract][Full Text] [Related]
6. Causes of death in mucopolysaccharidoses. Rintz E; Banacki M; Ziemian M; Kobus B; Wegrzyn G Mol Genet Metab; 2024 Jul; 142(3):108507. PubMed ID: 38815294 [TBL] [Abstract][Full Text] [Related]
7. Transcriptomic Changes Related to Cellular Processes with Particular Emphasis on Cell Activation in Lysosomal Storage Diseases from the Group of Mucopolysaccharidoses. Rintz E; Gaffke L; Podlacha M; Brokowska J; Cyske Z; Węgrzyn G; Pierzynowska K Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32366041 [TBL] [Abstract][Full Text] [Related]
8. Abnormalities in the hair morphology of patients with some but not all types of mucopolysaccharidoses. Malinowska M; Jakóbkiewicz-Banecka J; Kloska A; Tylki-Szymańska A; Czartoryska B; Piotrowska E; Wegrzyn A; Wegrzyn G Eur J Pediatr; 2008 Feb; 167(2):203-9. PubMed ID: 17361416 [TBL] [Abstract][Full Text] [Related]
9. Dysregulation of genes coding for proteins involved in metabolic processes in mucopolysaccharidoses, evidenced by a transcriptomic approach. Pierzynowska K; Deresz P; Węgrzyn G; Gaffke L Metab Brain Dis; 2023 Aug; 38(6):2133-2144. PubMed ID: 37195412 [TBL] [Abstract][Full Text] [Related]
10. Gene Expression-Related Changes in Morphologies of Organelles and Cellular Component Organization in Mucopolysaccharidoses. Gaffke L; Pierzynowska K; Rintz E; Cyske Z; Giecewicz I; Węgrzyn G Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803318 [TBL] [Abstract][Full Text] [Related]
11. Mucopolysaccharidoses in Brazil: what happens from birth to biochemical diagnosis? Vieira T; Schwartz I; Muñoz V; Pinto L; Steiner C; Ribeiro M; Boy R; Ferraz V; de Paula A; Kim C; Acosta A; Giugliani R Am J Med Genet A; 2008 Jul; 146A(13):1741-7. PubMed ID: 18546277 [TBL] [Abstract][Full Text] [Related]
12. Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations - Neurological signs and symptoms. Shapiro EG; Jones SA; Escolar ML Mol Genet Metab; 2017 Dec; 122S():1-7. PubMed ID: 29074036 [TBL] [Abstract][Full Text] [Related]
13. Cell cycle disturbances in mucopolysaccharidoses: Transcriptomic and experimental studies on cellular models. Brokowska J; Gaffke L; Pierzynowska K; Cyske Z; Węgrzyn G Exp Biol Med (Maywood); 2022 Sep; 247(18):1639-1649. PubMed ID: 36000158 [TBL] [Abstract][Full Text] [Related]
14. Substrate reduction therapies for mucopolysaccharidoses. Jakóbkiewicz-Banecka J; Piotrowska E; Gabig-Cimińska M; Borysiewicz E; Słomińska-Wojewódzka M; Narajczyk M; Węgrzyn A; Węgrzyn G Curr Pharm Biotechnol; 2011 Nov; 12(11):1860-5. PubMed ID: 21902626 [TBL] [Abstract][Full Text] [Related]
15. Separation of sulfated urinary glycosaminoglycans by high-resolution electrophoresis for isotyping of mucopolysaccharidoses in Malaysia. Nor A; Zabedah MY; Norsiah MD; Ngu LH; Suhaila AR Malays J Pathol; 2010 Jun; 32(1):35-42. PubMed ID: 20614724 [TBL] [Abstract][Full Text] [Related]
16. Practical management of behavioral problems in mucopolysaccharidoses disorders. Escolar ML; Jones SA; Shapiro EG; Horovitz DDG; Lampe C; Amartino H Mol Genet Metab; 2017 Dec; 122S():35-40. PubMed ID: 29170079 [TBL] [Abstract][Full Text] [Related]
17. Complex Changes in the Efficiency of the Expression of Many Genes in Monogenic Diseases, Mucopolysaccharidoses, May Arise from Significant Disturbances in the Levels of Factors Involved in the Gene Expression Regulation Processes. Cyske Z; Gaffke L; Pierzynowska K; Węgrzyn G Genes (Basel); 2022 Mar; 13(4):. PubMed ID: 35456399 [TBL] [Abstract][Full Text] [Related]